Interferon alpha-2a

【Product name】PEGASYS

[English common name]Nterferon alpha-2a

[Chinese common name]Interferon alpha-2a

[English name]

[Chinese other name]

[indications]
Peginterferon alfa-2a injection:
1. Chronic hepatitis BThis product is suitable for the treatment of chronic hepatitis B in adults. Patients cannot be in decompensated liver disease, and chronic hepatitis B must be diagnosed by serum markers (transferase, HBsAg, HBV DNA). Histological evidence is usually also required.
2. Chronic hepatitis C This product is suitable for adult patients with chronic hepatitis C who have not received treatment before treatment. Patients must have no liver decompensation, and chronic hepatitis C must be confirmed by serum markers (anti-HCV antibodies and HCV RNA). Usually the diagnosis is confirmed by histology. This product is best used in combination with ribavirin when treating this disease. This product can be used alone in the treatment of ribavirin intolerance or contraindications. The study of single drug therapy for patients with normal transaminase has not been conducted.
Recombinant human interferon alpha-2a injection: Luojing is suitable for the following treatments.
1. Lymphoid or hematopoietic system tumor hairy cell leukemia.Multiple myelomaLow-grade non-Hodgkin's lymphoma. Skin T-cell lymphoma.Chronic myeloid leukemia. Thrombosis associated with myeloproliferative diseases.
2. Solid tumors have no history of opportunistic infections in patients with AIDS-related Kaposi's sarcoma. Recurrent or metastatic renal cell carcinoma. Metastatic malignant melanoma.
3. Viral diseases with adult chronic active hepatitis B patients with HBV-DNA, DNA polymerase-positive or HBeAg-positive viral replication markers.
Recombinant human interferon alpha-2a for injection:
1. Viral disease: adult chronic active hepatitis B patients with HBV-DNA, DNA polymerase-positive or HBeAg-positive viral replication markers, with HCV antibody-positive and alanine aminotransferase (ALT), but not accompanied by Liver function decompensation (Child classification A) adult acute and chronic hepatitis C patients, condyloma acuminata, herpes zoster, pediatric viral pneumonia and upper respiratory tract infection, chronic cervicitis, hepatitis D and so on.
2. Tumor: hairy cell leukemia, multiple myeloma, non-Hodgkin's lymphoma,Chronic leukemiaAnd Kaposi's sarcoma, kidney cancer, laryngeal papilloma, melanoma, mycosis fungoides, bladder cancer, basal cell carcinoma, multiple myeloma, and the like.

【Dosage】
Peginterferon alfa-2a injection: This product must be treated by a physician who has experienced treatment of chronic hepatitis B and C. Please also refer to the instructions of ribavirin when using in combination with ribavirin.
Recombinant human interferon alpha-2a injection:
1. The initial dose of hairy cell leukemia is 3 million international units per day, subcutaneously or intramuscularly, 16 to 24 weeks. If the tolerance is poor, the daily dose should be reduced to 1.5 million international units, or the number of medications should be changed to 3 times a week, and the dose and number of medications can be reduced at the same time. The maintenance dose is 3 million international units each time, subcutaneously or intramuscularly 3 times a week. If the tolerance is poor, each dose is reduced to 1.5 million international units, 3 times a week. After about 6 months of treatment with the drug, the doctor decides whether to continue taking the drug for patients with good efficacy or for discontinuing the drug for patients with poor efficacy. There are also patients who continue to receive treatment for up to 20 months. The optimal course of treatment of hairy cell leukemia has not yet been determined.
Recombinant human interferon alpha-2a for injection:
1. Hairy cell leukemia starting dose: 3 million international units per day, subcutaneous or intramuscular injection, 16 to 24 weeks. If the tolerance is poor, the daily dose should be reduced to 1.5 million international units, or the number of medications should be changed to twice a week, and the dose and number of medications can be reduced at the same time.
(1) Maintenance dose: 2 million international units each time, subcutaneous or intramuscular injection 3 times a week. If the tolerance is poor, the daily dose is reduced to 1.5 million international units, 3 times a week.
(2) Treatment: After applying the drug for about 6 months, the doctor will decide whether to continue taking the drug for patients with good curative effect or to terminate the drug for patients with poor efficacy.

[Storage]
Peginterferon alfa-2a injection: sealed, protected from light, stored in the original packaging at 2 ~ 8 °C. Do not freeze. Drugs should be placed out of reach of children.
Recombinant human interferon alpha-2a injection: This product should be stored at 2 ~ 8 ° C, protected from light, do not freeze.
Recombinant human interferon alpha-2a for injection: shading, sealed and preserved.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

Description

name

Attention: The internal data of table “270” is corrupted!

product

Attention: The internal data of table “271” is corrupted!

product manual

Click to view interferon a-2a Chinese product description

Product information